J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Rang in Aktien
#3891
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Aktienkurs
$26.58
Zuletzt synchronisiert: 2026-07-23
Marktkapitalisierung
$4.24B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
38.14%
Land
IN
Handel J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategorie
Healthcare
Gewinn für J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Gewinn im Mar 2026 TTM: $105.10M
Laut den aktuellen Finanzberichten von J. B. Chemicals & Pharmaceuticals Limited betragen die aktuellen Gewinne des Unternehmens $105.10M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $90.13M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $67.56M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von J. B. Chemicals & Pharmaceuticals Limited von 2005 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $105.10M | 1.29% |
| 2025 | $103.76M | 15.12% |
| 2024 | $90.13M | 33.40% |
| 2023 | $67.56M | 1.58% |
| 2022 | $66.51M | -18.43% |
| 2021 | $81.54M | 76.06% |
| 2020 | $46.31M | 12.06% |
| 2019 | $41.33M | 38.74% |
| 2018 | $29.79M | -15.99% |
| 2017 | $35.46M | 12.49% |
| 2016 | $31.52M | 35.13% |
| 2015 | $23.33M | 59.89% |
| 2014 | $14.59M | -23.47% |
| 2013 | $19.06M | -88.54% |
| 2012 | $166.34M | 348.33% |
| 2011 | $37.10M | 12.53% |
| 2010 | $32.97M | 351.68% |
| 2009 | $7.30M | -33.14% |
| 2008 | $10.92M | -33.49% |
| 2007 | $16.41M | -11.60% |
| 2006 | $18.57M | 22.45% |
| 2005 | $15.16M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,578.98% |
IN
|
